Event JSON
{
"id": "c432d58f51e8d0d2291c5ab5ca69fedfc821d7f9058acec492e678e0e546f207",
"pubkey": "af947eb1ac2a94a86b48cbbda851396b8bcaa9aa59c9322e7c3da8264e0e9878",
"created_at": 1738486362,
"kind": 1,
"tags": [
[
"r",
"https://en.globes.co.il/en/article-1001501006#utm_source=RSS"
],
[
"subject",
"Analysts remain positive on Teva"
],
[
"published_at",
"1738493050"
],
[
"image",
"https://res.cloudinary.com/globes/image/upload/t_800X392/v1669041602/direct/Untitled-1_ngdpbe.jpg"
],
[
"p",
"af947eb1ac2a94a86b48cbbda851396b8bcaa9aa59c9322e7c3da8264e0e9878",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://res.cloudinary.com/globes/image/upload/t_800X392/v1669041602/direct/Untitled-1_ngdpbe.jpg"
],
[
"t",
"Israel:perspective"
],
[
"summary",
"The company's recent share price decline was largely attributed to its 2025 guidance, which fell short of expectations. However, analysts are focusing on the company's investments in its innovative pipeline and efforts to reduce debt, which they believe will drive long-term growth."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpq4728avdv9222s66gew76s5fedw9u42d2t8ynytnu8k5zvnswnpuq7qxnev\nhttps://res.cloudinary.com/globes/image/upload/t_800X392/v1669041602/direct/Untitled-1_ngdpbe.jpg\nThe company's 2025 guidance sent its share price tumbling, but analysts stress its investment in its innovative pipeline and debt reduction.\nhttps://en.globes.co.il/en/article-1001501006#utm_source=RSS",
"sig": "ff65337dde03fa711169a688746e4e0e14387bc9210f863854358f2dd50aec3e0081717858a72b9598e4d6741eb5da415ae171890e7d8a2cd6a630590d1bb2c5"
}
